MedTrace Logo

Intraperitoneal Lidocaine and Bupivacaine for Postoperative Pain After Laparoscopic Surgery

NCT07775599 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-08-20

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the safety and efficacy of combined intraperitoneal local anesthetic instillation and port-site infiltration using lidocaine and bupivacaine in adults aged 18 to 60 undergoing elective laparoscopic abdominal surgeries (such as laparoscopic cholecystectomy, appendectomy, or hernia repair). The main questions it aims to answer are: Does combined intraperitoneal local anesthetic instillation and port-site infiltration reduce immediate and early (up to 4 hours) postoperative pain scores? Does this intervention reduce the early need for additional postoperative analgesics and shorten the length of hospital stay? Researchers will compare the treatment group receiving lidocaine (2%) and bupivacaine (0.5%) by intraperitoneal instillation and port-site infiltration with a control group receiving normal saline by the corresponding routes to determine whether the local anesthetic intervention reduces postoperative pain and analgesic requirements. Participants will undergo scheduled elective laparoscopic abdominal surgery and receive either the local anesthetic intervention or normal saline during the surgical procedure. Pain will be assessed using the Visual Analog Scale (VAS) immediately after surgery in the recovery room and again at 2 and 4 hours after surgery. Analgesic needs will be monitored and documented, and total hospital stay will be recorded.

Conditions

  • Abdominal Laparoscopic and/or Robotic Surgery
  • Local Anasthesia
  • Post Operative Pain, Acute
  • Lidocaine
  • Bupivacaine

Interventions

DRUG

Lidocaine

10 mL lidocaine 2% administered intraoperatively by intraperitoneal instillation and port-site infiltration

OTHER

Placebo Normal Saline (NS)

Intraoperative intraperitoneal instillation and port-site infiltration of normal saline

DRUG

Bupivacaine

10 mL bupivacaine 0.5% administered intraoperatively by intraperitoneal instillation and port-site infiltration

Sponsors & Collaborators

  • Misr University for Science and Technology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-06
Primary Completion
2026-07-05
Completion
2026-07-05

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07775599 on ClinicalTrials.gov